FY2029 Earnings Estimate for AnaptysBio Issued By Wedbush

AnaptysBio, Inc. (NASDAQ:ANAB) – Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for AnaptysBio in a report released on Monday, February 3rd. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings of ($4.04) per share for the year. Wedbush has a “Outperform” rating and a $40.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

ANAB has been the subject of a number of other reports. Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Truist Financial lowered their price target on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. BTIG Research cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $41.45.

AnaptysBio Stock Down 7.1 %

Shares of ANAB stock opened at $16.66 on Tuesday. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31. The firm has a market capitalization of $506.96 million and a price-to-earnings ratio of -2.74. The firm has a fifty day moving average of $17.38 and a 200-day moving average of $27.01.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7.92 million.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently modified their holdings of ANAB. The Manufacturers Life Insurance Company raised its stake in AnaptysBio by 49.8% during the second quarter. The Manufacturers Life Insurance Company now owns 25,312 shares of the biotechnology company’s stock worth $634,000 after buying an additional 8,418 shares during the last quarter. Algert Global LLC increased its stake in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 1,078 shares in the last quarter. SG Americas Securities LLC bought a new stake in AnaptysBio in the third quarter valued at $405,000. nVerses Capital LLC increased its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares in the last quarter.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc purchased 65,184 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was purchased at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the purchase, the director now owns 7,860,180 shares of the company’s stock, valued at approximately $101,553,525.60. The trade was a 0.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 33.70% of the company’s stock.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.